Peer Review History

Original SubmissionDecember 6, 2023

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Robert Jeenchen Chen, Editor

PONE-D-23-40889+Effect of Dexamethasone Pretreatment Using Deep Learning on the Surgical Effect of Patients with Gastrointestinal TumorsPLOS ONE

Dear Dr. Fu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Lots of English errors from Title, Abstract,...  Many incomplete sentences...Please re-write and go through English editing! I should reject this manuscript upfront.  Just give the authors another chance!

Please submit your revised manuscript by Apr 07 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

PONE-D-23-40889

+Effect of Dexamethasone Pretreatment Using Deep Learning on the Surgical Effect of Patients with Gastrointestinal Tumors

PLOS ONE

Dear Dr. Fu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Lots of English errors from Title, Abstract,... Many incomplete sentences...

Please re-write and go through English editing!

I should reject this manuscript upfront. Just give the authors another chance!

Reply: Thank you for your suggestion. I have proof the whole article.

Please submit your revised manuscript by Apr 07 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

Reply: Thank you for your suggestion. I have adjusted the text according to the style you provided, including title format, paragraph space, chart title format, reference format, and provided TIFF format images.

2. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Reply: Thank you for your suggestion. The above data have been provided.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

Reply: Thank you for your suggestion. I have has added the name of the ethics committee in the methods section, and the signing of informed consent forms has been described in the inclusion criteria.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Robert Jeenchen Chen, Editor

PONE-D-23-40889R1Effect of Dexamethasone Pretreatment Using Deep Learning on the Surgical Effect of Patients with Gastrointestinal TumorsPLOS ONE

Dear Dr. Fu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 17 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments:

Please revise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: thanks

the revised paper is better than the original one

i recommends adding recent references (in the last 5 years)

your hard work is clear

for my point of view the paper now is suitable for publication.

congratulations

Reviewer #2: I have reviewed the revised submission. After going through it, I still seem to require more clarifications.

1. Please clarify two different statements written about exp and ctrl groups:

In Abstract: The participants were randomly assigned to either the control (Ctrl) group (n=40) or the experimental (Exp) group (n=40). The Ctrl group received a 2 mL intravenous injection of 0.9% saline solution 1-2 hours prior to surgical incision, while

the Exp group received a 10 mg (2 mL) intravenous injection of dexamethasone at the same time point.

While in Research Object heading: Participants were randomly assigned to two groups based on the preoperative anesthesia pretreatment methods implemented. In the control (Ctrl) group, patients received an intravenous injection of 10 mg (2 mL)

dexamethasone administered manually 1-2 hours prior to skin incision. Conversely, the experimental

(Exp) group underwent anesthesia detection utilizing deep learning technology in addition to the

anesthesia pretreatment protocol administered to the Ctrl group. these seem to be opposing statements.

2. Please clarify the use of Deep Learning algorithms as a research tool for this comparative study of two groups. You have mentioned that these were used in a sample of 10 patients. What was the rationale for not using in all patients?

3. To me as a clinician the study seems to compare the beneficial effects of pre-anesthetic use of dexamethasone on post-operative cognitive behaviour and Gastrointestinal recovery of patients. Dexamethasone affects teh neuronal networks of the body, part of our deep learning networks. Actual tests performed in both groups were the use of MoCA, GI functional tests and other lab tests. The table 1 based on Deep Learning is given for a sample of 10 patients. My query is: even if you remove the table 1and do not employ deep learning algorithms in this study, how would it affect your results? Your data is still showing the beneficial effectg of using dexamethasone. Please clarify in your introduction and methodology how was this technology used and what difference was noted in two groups.

In Conclusion: You have mentioned the clear benefits of using Deep Learning processing on post-operative recovery of patients. It seems this statement has been used as synonym for use of dexamethasone as there is no mention of the medication in concluding statements. Please clarify it, too.

In summary, please make your manuscript as elaborate, as possible, for clinicians and physicians to understand clearly.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: hazim alhiti

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

Reviewer #1: thanks

the revised paper is better than the original one

i recommends adding recent references (in the last 5 years)

Reply: Thank you for your suggestion. I have reviewed the literature and ensured that the most recent references are added where applicable to keep our content up-to-date with the latest research findings and developments.

your hard work is clear

for my point of view the paper now is suitable for publication.

congratulations

Reviewer #2: I have reviewed the revised submission. After going through it, I still seem to require more clarifications.

1. Please clarify two different statements written about exp and ctrl groups:

In Abstract: The participants were randomly assigned to either the control (Ctrl) group (n=40) or the experimental (Exp) group (n=40). The Ctrl group received a 2 mL intravenous injection of 0.9% saline solution 1-2 hours prior to surgical incision, while

the Exp group received a 10 mg (2 mL) intravenous injection of dexamethasone at the same time point.

While in Research Object heading: Participants were randomly assigned to two groups based on the preoperative anesthesia pretreatment methods implemented. In the control (Ctrl) group, patients received an intravenous injection of 10 mg (2 mL)

dexamethasone administered manually 1-2 hours prior to skin incision. Conversely, the experimental

(Exp) group underwent anesthesia detection utilizing deep learning technology in addition to the

anesthesia pretreatment protocol administered to the Ctrl group. these seem to be opposing statements.

Reply: Thank you for providing the modification suggestions. We understand your concerns and appreciate your feedback.

The inconsistency between the description of the experimental group and the control group in the abstract and research subject title is our mistake. Here, we clarify as follows:

In our study, we did have two groups: the control group (Ctrl) and the experimental group (Exp). The description mentioned in the title of the research subjects is correct, that is, the control group received dexamethasone injection, while the experimental group received dexamethasone injection assisted by a deep learning-based anesthesia detection system.

However, the description in the abstract is inaccurate. We deeply apologize for this. The correct description should be: participants were randomly assigned to a control group and an experimental group. In the control group, patients manually received intravenous injection of dexamethasone 1-2 hours before the skin incision. On the contrary, the experimental group used deep learning techniques to monitor anesthesia status on the basis of the control group.

We thank you again for pointing out this issue and sincerely apologize for any inconvenience caused by this confusion. We have revised the title to reflect the true situation of the experiment.

2. Please clarify the use of Deep Learning algorithms as a research tool for this comparative study of two groups. You have mentioned that these were used in a sample of 10 patients. What was the rationale for not using in all patients?

Reply: Thank you for providing the modification suggestions. Regarding the application of deep learning algorithms in anesthesia detection systems evaluated using 10 patients in the study, no comparison was made between the two groups of patients. Its main purpose was to test the performance of the deep learning-based BIS detection system constructed in the study. The reason why it was not used in all patients is because deep learning algorithms usually require a large amount of computing resources and time for training and analysis. In some cases, we may not have sufficient computing resources to process data for the entire patient population. Therefore, to avoid resource waste, we choose to use these algorithms in smaller samples.

3. To me as a clinician the study seems to compare the beneficial effects of pre-anesthetic use of dexamethasone on post-operative cognitive behaviour and Gastrointestinal recovery of patients. Dexamethasone affects teh neuronal networks of the body, part of our deep learning networks. Actual tests performed in both groups were the use of MoCA, GI functional tests and other lab tests. The table 1 based on Deep Learning is given for a sample of 10 patients. My query is: even if you remove the table 1and do not employ deep learning algorithms in this study, how would it affect your results? Your data is still showing the beneficial effectg of using dexamethasone. Please clarify in your introduction and methodology how was this technology used and what difference was noted in two groups.

In Conclusion: You have mentioned the clear benefits of using Deep Learning processing on post-operative recovery of patients. It seems this statement has been used as synonym for use of dexamethasone as there is no mention of the medication in concluding statements. Please clarify it, too.

In summary, please make your manuscript as elaborate, as possible, for clinicians and physicians to understand clearly.

Reply: Thank you very much for reviewing our research and providing valuable suggestions for revisions. Here is my response to your question and corresponding modifications:

(1) Based on the above modifications, the control group was given dexamethasone, while the experimental group was given dexamethasone with the assistance of a deep learning-based anesthesia detection system. Therefore, if Table 1 is deleted and the deep learning algorithm is not used for grouping, it will not form a control analysis. In addition, in the introduction and methodology, we will provide a detailed explanation of how deep learning algorithms are applied in our research, clarify the differences between the two groups, and ensure that readers can clearly understand the technical details in the study.

(2) In the conclusion section, we will clarify that the benefits of deep learning processing are not synonymous with the use of dexamethasone. We will clarify this point and ensure that the conclusion section clearly expresses the importance of dexamethasone in postoperative recovery of patients, while not confusing the benefits of deep learning processing with the effectiveness of drug therapy.

We will write the manuscript as detailed as possible according to your suggestions to ensure that clinical doctors and doctors can clearly understand our research. Thank you again for your suggestions and review.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Robert Jeenchen Chen, Editor

Effect of Dexamethasone Pretreatment Using Deep Learning on the Surgical Effect of Patients with Gastrointestinal Tumors

PONE-D-23-40889R2

Dear Dr. Fu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Robert Jeenchen Chen, MD, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: bias is clear

ethical approval was clear

the topic is not unique

the paper looks sound after revision

congratulations

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: hazim alhiti

Reviewer #2: Yes: Mohammed Amir

**********

Formally Accepted
Acceptance Letter - Robert Jeenchen Chen, Editor

PONE-D-23-40889R2

PLOS ONE

Dear Dr. Fu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Robert Jeenchen Chen

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .